The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 08, 2015
Filed:
Apr. 01, 2011
Celia Berta Fernandez Ortega, La Habana, CU;
Anna Caridys Ramírez Suárez, La Habana, CU;
Dionne Casillas Casanova, La Habana, CU;
Taimi Emelia Paneque Guerrero, La Habana, CU;
Raimundo Ubieta Gómez, La Habana, CU;
Marta Dubed Echevarria, La Habana, CU;
Leonor Margarita Navea Leyva, La Habana, CU;
Lila Rosa Castellanos Serra, La Habana, CU;
Carlos Antonio Duarte Cano, La Habana, CU;
Viviana Falcón Cama, La Habana, CU;
Osvaldo Reyes Acosta, La Habana, CU;
Celia Berta Fernandez Ortega, La Habana, CU;
Anna Caridys Ramírez Suárez, La Habana, CU;
Dionne Casillas Casanova, La Habana, CU;
Taimi Emelia Paneque Guerrero, La Habana, CU;
Raimundo Ubieta Gómez, La Habana, CU;
Marta Dubed Echevarria, La Habana, CU;
Leonor Margarita Navea Leyva, La Habana, CU;
Lila Rosa Castellanos Serra, La Habana, CU;
Carlos Antonio Duarte Cano, La Habana, CU;
Viviana Falcón Cama, La Habana, CU;
Osvaldo Reyes Acosta, La Habana, CU;
CENTRO DE INGENIERIA GENETICA Y BIOTECHNOLOGIA, La Habana, CU;
Abstract
The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g. by transcriptional control using interfering RNA) or by using peptides that disrupt the cytoskeleton.